Sign in
Not yet taking people in NetherlandsPhase 3

Tests mitapivat effects on brain blood flow in sickle cell disease

Tests mitapivat in adults with sickle cell anaemia to study brain blood flow.

Key facts

Who runs it
Amsterdam UMC Stichting
Where
Amsterdam, NetherlandsSee the site
Registry title
The Effect of Mitapivat on Cerebral Perfusion and Oxygen Metabolism in Sickle Cell Disease
Status
Not yet recruiting
Phase
Phase 3
People taking part
20 people, planned
Started
1 Apr 2025
Planned end
1 Apr 2026
Type of study
Interventional
Record updated
8 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with sickle cell disease (HbSS or HbSβ0-thalassemia) and low hemoglobin, to study how mitapivat affects blood flow and oxygen use in the brain.

Age
18 years and older
Sex
All sexes
Disease stage
Sickle cell disease with a documented HbSS or HbSβ0-thalassemia genotype, and hemoglobin of 10.5 g/dL or lower
Earlier treatment
If taking hydroxyurea, the dose must have been stable for at least 90 days. No regular blood transfusions, and no transfusion in the last 90 days. No erythropoietin or other blood growth factors in the last 28 days.
Biomarker or test result
Documented HbSS or HbSβ0-thalassemia genotype, confirmed by lab testing if needed. Hemoglobin of 10.5 g/dL or lower.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • History of overt stroke
  • Severe kidney problems (eGFR below 30 mL/min)
  • Hospitalized for sickle cell crisis or a vaso-occlusive event in the last 14 days
  • Cannot have an MRI or acetazolamide, or is allergic to mitapivat or sulphonamide-based drugs

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Documented SCD genotype (HbSS, HbSβ0-thalassemia) which may be based on history of laboratory testing or must be confirmed by laboratory testing during screening
  • Age 18 and above
  • Hemoglobin (Hb) ≤10.5 g/dL
  • For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for at least 90 days prior to participation and with no anticipated need for dose adjustments
  • Female participants of childbearing potential should agree to be abstinent as part of their usual lifestyle or use a highly effective method of contraception. Furthermore, due to the potential for mitapivat to reduce the effectiveness of hormonal contraceptives, women using hormonal contraception must also use an acceptable barrier method while enrolled in the study and for at least 28 days after their last dose. Women using non-hormonal methods of contraception as a highly effective method do not need to use an additional barrier method
  • Participant has provided documented informed consent or assent (the informed consent form [ICF] must be reviewed and signed by each participant; the participant’s legal representative or legal guardian, and the participant’s assent must be obtained)

Who cannot take part

  • History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent, including but not limited to the following: • Unstable angina pectoris or myocardial infarction or elective coronary intervention. • Congestive heart failure requiring hospitalization. • Uncontrolled clinically significant arrhythmias
  • Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable)
  • Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational agent (or medical device)
  • Patients who are receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or have received a RBC transfusion for any reason within 90 days before participation
  • Patients receiving with voxelotor or inhibitors of CYP3A4
  • Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days prior participation
  • Participants with clinically significant bacterial, fungal, parasitic or viral infection which require therapy: • Participants with acute bacterial infection requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed. • Participants with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive
  • History of malignancy within the past 2 years prior to participation requiring chemotherapy and/or radiation (with the exception of local therapy for non-melanoma skin malignancy)
  • Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent
  • Patients with history of overt stroke
  • Patients allergic to mitapivat or sulphonamide-based drugs
  • Hepatic dysfunction characterized by alanine aminotransferase (ALT) >2.5 × ULN
  • No informed consent has been given
  • Severe renal dysfunction (estimated glomerular filtration rate <30mL/min)
  • Receipt of erythropoietin or other hematopoietic growth factors within 28 days of signing ICF or anticipated need for such agents during the study
  • Contra-indication for MRI or acetazolamide
  • Female who is breast feeding or pregnant

Where in Netherlands

  • Amsterdam UMC StichtingAmsterdam, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To assess the effect of mitapivat on the cerebral oxygen metabolism (CBF)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
The Effect of Mitapivat on Cerebral Perfusion and Oxygen Metabolism in Sickle Cell Disease
Plain-language title
Tests mitapivat effects on brain blood flow in sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
8 May 2026